Polymorphisms in vascular endothelial growth factor receptor 2 are associated with better response rates to ranibizumab treatment in age-related macular degeneration

Ophthalmology

Volumn 121, Issue 4, 2014, Pages 905-910

  Hermann, Manuel M ^a   Van Asten, Freekje ^b   Muether, Philipp S ^a   Smailhodzic, Dzenita ^b   Lichtner, Peter ^c   Hoyng, Carel B ^b   Kirchhof, Bernd ^a   Grefkes, Christian ^a,d   Den Hollander, Anneke I ^b   Fauser, Sascha ^a  

^a UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^c INSTITUTE OF EPIDEMIOLOGY   (Germany)

^d MAX PLANCK INSTITUTE FOR NEUROLOGICAL RESEARCH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

PIGMENT EPITHELIUM DERIVED FACTOR; PLACENTAL GROWTH FACTOR; RANIBIZUMAB; VASCULOTROPIN A; VASCULOTROPIN B; VASCULOTROPIN C; VASCULOTROPIN D; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2; VASCULOTROPIN RECEPTOR 3;

ADULT; AGED; ALLELE; ARTICLE; FEMALE; GENETIC ASSOCIATION; GENOTYPE; HUMAN; LINEAR REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTICENTER STUDY; OPTICAL COHERENCE TOMOGRAPHY; PRIORITY JOURNAL; RETINA MACULA AGE RELATED DEGENERATION; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT DURATION; TREATMENT RESPONSE; UNIVARIATE ANALYSIS; VERY ELDERLY; VISUAL ACUITY;

AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; COLORING AGENTS; FEMALE; FLUORESCEIN ANGIOGRAPHY; GENOTYPE; GENOTYPING TECHNIQUES; HUMANS; INDOCYANINE GREEN; MALE; MIDDLE AGED; POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE NUCLEOTIDE; TOMOGRAPHY, OPTICAL COHERENCE; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2; VISUAL ACUITY; WET MACULAR DEGENERATION;

EID: 84897954233     PISSN: 01616420     EISSN: 15494713     Source Type: Journal    
DOI: 10.1016/j.ophtha.2013.10.047     Document Type: Article

References (24)

1. F. Abedi, S. Wickremasinghe, and A.J. Richardson et al. Genetic influences on the outcome of anti-vascular endothelial growth factor treatment in neovascular age-related macular degeneration Ophthalmology 120 2013 1641 1648
2. F. Abedi, S. Wickremasinghe, and A.J. Richardson et al. Variants in the VEGFA gene and treatment outcome after anti-VEGF treatment for neovascular age-related macular degeneration Ophthalmology 120 2013 115 121
3. M.A. Brantley Jr., A.M. Fang, and J.M. King et al. Association of complement factor H and LOC387715 genotypes with response of exudative age-related macular degeneration to intravitreal bevacizumab Ophthalmology 114 2007 2168 2173
4. W. Chang, D.H. Noh, M. Sagong, and I.T. Kim Pharmacogenetic association with early response to intravitreal ranibizumab for age-related macular degeneration in a Korean population Mol Vis [serial online] 19 2013 702 709 Available at http://www.molvis.org/molvis/v19/702/ Accessed October 28, 2013
5. H. Chen, K.D. Yu, and G.Z. Xu Association between variant Y402H in age-related macular degeneration (AMD) susceptibility gene CFH and treatment response of AMD: a meta-analysis PLoS One [serial online] 7 2012 e42464 Available at http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone. 0042464 Accessed October 28, 2013
6. P.J. Francis The influence of genetics on response to treatment with ranibizumab (Lucentis) for age-related macular degeneration: the Lucentis Genotype Study (an American Ophthalmological Society thesis) Trans Am Ophthalmol Soc 109 2011 115 156
7. B. Kloeckener-Gruissem, D. Barthelmes, and S. Labs et al. Genetic association with response to intravitreal ranibizumab in patients with neovascular AMD Invest Ophthalmol Vis Sci 52 2011 4694 4702
8. S. Lazzeri, M. Figus, and P. Orlandi et al. VEGF-A polymorphisms predict short-term functional response to intravitreal ranibizumab in exudative age-related macular degeneration Pharmacogenomics 14 2013 623 630
9. M. McKibbin, M. Ali, and S. Bansal et al. CFH, VEGF and HTRA1 promoter genotype may influence the response to intravitreal ranibizumab therapy for neovascular age-related macular degeneration Br J Ophthalmol 96 2012 208 212
10. C. Nischler, H. Oberkofler, and C. Ortner et al. Complement factor H Y402H gene polymorphism and response to intravitreal bevacizumab in exudative age-related macular degeneration [report online] Acta Ophthalmol 89 2011 e344 e349
11. D. Smailhodzic, P.S. Muether, and J. Chen et al. Cumulative effect of risk alleles in CFH, ARMS2, and VEGFA on the response to ranibizumab treatment in age-related macular degeneration Ophthalmology 119 2012 2304 2311
12. S.J. Teper, A. Nowinska, and J. Pilat et al. Involvement of genetic factors in the response to a variable-dosing ranibizumab treatment regimen for age-related macular degeneration Mol Vis [serial online] 16 2010 2598 2604 Available at http://www.molvis.org/molvis/v16/a278/ Accessed October 28, 2013
13. J. Tian, X. Qin, and K. Fang et al. Association of genetic polymorphisms with response to bevacizumab for neovascular age-related macular degeneration in the Chinese population Pharmacogenomics 13 2012 779 787
14. V.M. Wang, R.B. Rosen, and C.B. Meyerle et al. Suggestive association between PLA2G12A single nucleotide polymorphism rs2285714 and response to anti-vascular endothelial growth factor therapy in patients with exudative age-related macular degeneration Mol Vis [serial online] 18 2012 2578 2585 Available at http://www.molvis.org/molvis/v18/a267/ Accessed October 28, 2013
15. K. Yamashiro, K. Tomita, and A. Tsujikawa et al. Factors associated with the response of age-related macular degeneration to intravitreal ranibizumab treatment Am J Ophthalmol 154 2012 125 136
16. A.Y. Lee, A.K. Raya, and S.M. Kymes et al. Pharmacogenetics of complement factor H (Y402H) and treatment of exudative age-related macular degeneration with ranibizumab Br J Ophthalmol 93 2009 610 613
17. A.N. Witmer, G.F. Vrensen, C.J. Van Noorden, and R.O. Schlingemann Vascular endothelial growth factors and angiogenesis in eye disease Prog Retin Eye Res 22 2003 1 29
18. P.I. de Bakker, R. Yelensky, and I. Pe'er et al. Efficiency and power in genetic association studies Nat Genet 37 2005 1217 1223
19. K.R. Koch, P.S. Muether, and M.M. Hermann et al. Subjective perception versus objective outcome after intravitreal ranibizumab for exudative AMD Graefes Arch Clin Exp Ophthalmol 250 2012 201 209
20. K.M. Droege, P.S. Muether, and M.M. Hermann et al. Adherence to ranibizumab treatment for neovascular age-related macular degeneration in real life Graefes Arch Clin Exp Ophthalmol 251 2013 1281 1284
21. R.P. Finger, P. Wiedemann, and F. Blumhagen et al. Treatment patterns, visual acuity and quality-of-life outcomes of the WAVE study-A noninterventional study of ranibizumab treatment for neovascular age-related macular degeneration in Germany Acta Ophthalmol 91 2013 540 546
22. AMD Gene Consortium Seven new loci associated with age-related macular degeneration Nat Genet 45 2013 433 439
23. D. Lambrechts, B. Claes, and P. Delmar et al. VEGF pathway genetic variants as biomarkers of treatment outcome with bevacizumab: an analysis of data from the AViTA and AVOREN randomised trials Lancet Oncol 13 2012 724 733
24. CATT Research Group Ranibizumab and bevacizumab for neovascular age-related macular degeneration N Engl J Med 364 2011 1897 1908